FIG. 2.

MICs of rifampin (A), fusidic acid (B), erythromycin (C), clindamycin (D), azithromycin (E), and vancomycin (F) for E. coli mutants defective in the synthesis of LPS core oligosaccharide or lipid A as well as for their parent-type controls. Susceptibility determinations were performed at 28°C (○) and 37°C (■). Lanes: 1, strain IH3080 (smooth, encapsulated control); 2, strain SM105 (K-12 wild-type control); 3, strain MLK1067 (msbB); 4, strain MLK53 (htrB); 5, strain MLK986 (msbB htrB); 6, strain D21f2 (rfa, LPS chemotype Re); 7, strain CDH23-213 (lpxD); and 8, strain SM101 (lpxA). Susceptibility of a gram-positive bacterium, M. luteus ATCC 9341 (lanes 9), is shown for comparison.